Liver cancer software tool tested, but study ends early
NCT ID NCT05582018
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This pilot study tested a software called BioTraceIO 360, designed to help doctors plan and monitor liver tumor ablation (a procedure that destroys tumors with heat). The study aimed to enroll 30 people with liver cancer, but was terminated early with only 4 participants. The goal was to see if the software's suggestions matched what doctors would do on their own.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Einstein Medical Center
Philadelphia, Pennsylvania, 19141, United States
Conditions
Explore the condition pages connected to this study.